Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation

K. Buser, M. Bacchi, A. Goldhirsch, R. Greiner, P. Diener, C. Sessa, W. F. Jungi, M. Forni, S. Leyvraz, V. Engeler

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The primary aim was to induce a high number of pCR in early (FIGO IC, IIB + C) - and advanced (FIGO III-IV stage ovarian cancer with a surgery plus 4 cycles of cisplatin and melphalan (PAMP) regimen. The second objective was to prevent relapse with WAR in patients in remission after chemotherapy. Patients and methods: 218 eligible patients were treated after staging laparotomy with cisplatin 80 mg/sqm i.v. on day 1 and melphalan 12 mg/sqm i.v. on day 2 q 4 weeks. Response was verified by second-look laparotomy. WAR was carried out with the open field technique on a linear accelerator (daily dose: 1.3 Gy, total dose: 29.9 Gy) in patients with pathological or clinical CR or pathological PR with microscopical residual disease. Results: 146/218 patients (67%, 95% CI: 61%-73%) responded to PAMP: 56 (26%) achieved pCR, 24 (11%), cCR, 56 (26%) pPR and 10 (5%) cPR (c = clinical, p = pathological). Multivariate analyses revealed that in advanced stages (92 cases in remission), the achievement of pCR was the most important factor for longer time to failure (TTF) and survival. Only 51/118 (43%) patients in remission received WAR. Early-stage patients

Original languageEnglish
Pages (from-to)65-70
Number of pages6
JournalAnnals of Oncology
Volume7
Issue number1
Publication statusPublished - Jan 1996

Fingerprint

Ovarian Neoplasms
Radiation
Drug Therapy
Melphalan
Laparotomy
Cisplatin
Therapeutics
Particle Accelerators
Multivariate Analysis
Recurrence
Survival

Keywords

  • Advanced ovarian cancer
  • Chemotherapy
  • Cisplatin
  • Melphalan
  • Second-look surgery
  • Whole abdominal radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Buser, K., Bacchi, M., Goldhirsch, A., Greiner, R., Diener, P., Sessa, C., ... Engeler, V. (1996). Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation. Annals of Oncology, 7(1), 65-70.

Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation. / Buser, K.; Bacchi, M.; Goldhirsch, A.; Greiner, R.; Diener, P.; Sessa, C.; Jungi, W. F.; Forni, M.; Leyvraz, S.; Engeler, V.

In: Annals of Oncology, Vol. 7, No. 1, 01.1996, p. 65-70.

Research output: Contribution to journalArticle

Buser, K, Bacchi, M, Goldhirsch, A, Greiner, R, Diener, P, Sessa, C, Jungi, WF, Forni, M, Leyvraz, S & Engeler, V 1996, 'Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation', Annals of Oncology, vol. 7, no. 1, pp. 65-70.
Buser, K. ; Bacchi, M. ; Goldhirsch, A. ; Greiner, R. ; Diener, P. ; Sessa, C. ; Jungi, W. F. ; Forni, M. ; Leyvraz, S. ; Engeler, V. / Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation. In: Annals of Oncology. 1996 ; Vol. 7, No. 1. pp. 65-70.
@article{3e30a0e956a54073a6a430d8d513601f,
title = "Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation",
abstract = "Background: The primary aim was to induce a high number of pCR in early (FIGO IC, IIB + C) - and advanced (FIGO III-IV stage ovarian cancer with a surgery plus 4 cycles of cisplatin and melphalan (PAMP) regimen. The second objective was to prevent relapse with WAR in patients in remission after chemotherapy. Patients and methods: 218 eligible patients were treated after staging laparotomy with cisplatin 80 mg/sqm i.v. on day 1 and melphalan 12 mg/sqm i.v. on day 2 q 4 weeks. Response was verified by second-look laparotomy. WAR was carried out with the open field technique on a linear accelerator (daily dose: 1.3 Gy, total dose: 29.9 Gy) in patients with pathological or clinical CR or pathological PR with microscopical residual disease. Results: 146/218 patients (67{\%}, 95{\%} CI: 61{\%}-73{\%}) responded to PAMP: 56 (26{\%}) achieved pCR, 24 (11{\%}), cCR, 56 (26{\%}) pPR and 10 (5{\%}) cPR (c = clinical, p = pathological). Multivariate analyses revealed that in advanced stages (92 cases in remission), the achievement of pCR was the most important factor for longer time to failure (TTF) and survival. Only 51/118 (43{\%}) patients in remission received WAR. Early-stage patients",
keywords = "Advanced ovarian cancer, Chemotherapy, Cisplatin, Melphalan, Second-look surgery, Whole abdominal radiation",
author = "K. Buser and M. Bacchi and A. Goldhirsch and R. Greiner and P. Diener and C. Sessa and Jungi, {W. F.} and M. Forni and S. Leyvraz and V. Engeler",
year = "1996",
month = "1",
language = "English",
volume = "7",
pages = "65--70",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation

AU - Buser, K.

AU - Bacchi, M.

AU - Goldhirsch, A.

AU - Greiner, R.

AU - Diener, P.

AU - Sessa, C.

AU - Jungi, W. F.

AU - Forni, M.

AU - Leyvraz, S.

AU - Engeler, V.

PY - 1996/1

Y1 - 1996/1

N2 - Background: The primary aim was to induce a high number of pCR in early (FIGO IC, IIB + C) - and advanced (FIGO III-IV stage ovarian cancer with a surgery plus 4 cycles of cisplatin and melphalan (PAMP) regimen. The second objective was to prevent relapse with WAR in patients in remission after chemotherapy. Patients and methods: 218 eligible patients were treated after staging laparotomy with cisplatin 80 mg/sqm i.v. on day 1 and melphalan 12 mg/sqm i.v. on day 2 q 4 weeks. Response was verified by second-look laparotomy. WAR was carried out with the open field technique on a linear accelerator (daily dose: 1.3 Gy, total dose: 29.9 Gy) in patients with pathological or clinical CR or pathological PR with microscopical residual disease. Results: 146/218 patients (67%, 95% CI: 61%-73%) responded to PAMP: 56 (26%) achieved pCR, 24 (11%), cCR, 56 (26%) pPR and 10 (5%) cPR (c = clinical, p = pathological). Multivariate analyses revealed that in advanced stages (92 cases in remission), the achievement of pCR was the most important factor for longer time to failure (TTF) and survival. Only 51/118 (43%) patients in remission received WAR. Early-stage patients

AB - Background: The primary aim was to induce a high number of pCR in early (FIGO IC, IIB + C) - and advanced (FIGO III-IV stage ovarian cancer with a surgery plus 4 cycles of cisplatin and melphalan (PAMP) regimen. The second objective was to prevent relapse with WAR in patients in remission after chemotherapy. Patients and methods: 218 eligible patients were treated after staging laparotomy with cisplatin 80 mg/sqm i.v. on day 1 and melphalan 12 mg/sqm i.v. on day 2 q 4 weeks. Response was verified by second-look laparotomy. WAR was carried out with the open field technique on a linear accelerator (daily dose: 1.3 Gy, total dose: 29.9 Gy) in patients with pathological or clinical CR or pathological PR with microscopical residual disease. Results: 146/218 patients (67%, 95% CI: 61%-73%) responded to PAMP: 56 (26%) achieved pCR, 24 (11%), cCR, 56 (26%) pPR and 10 (5%) cPR (c = clinical, p = pathological). Multivariate analyses revealed that in advanced stages (92 cases in remission), the achievement of pCR was the most important factor for longer time to failure (TTF) and survival. Only 51/118 (43%) patients in remission received WAR. Early-stage patients

KW - Advanced ovarian cancer

KW - Chemotherapy

KW - Cisplatin

KW - Melphalan

KW - Second-look surgery

KW - Whole abdominal radiation

UR - http://www.scopus.com/inward/record.url?scp=13344286368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13344286368&partnerID=8YFLogxK

M3 - Article

C2 - 9081394

AN - SCOPUS:13344286368

VL - 7

SP - 65

EP - 70

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -